Orphanet Journal of Rare Diseases (Jun 2020)

Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study

  • Frédérique Audic,
  • Marta Gomez Garcia de la Banda,
  • Delphine Bernoux,
  • Paola Ramirez-Garcia,
  • Julien Durigneux,
  • Christine Barnerias,
  • Arnaud Isapof,
  • Jean-Marie Cuisset,
  • Claude Cances,
  • Christian Richelme,
  • Carole Vuillerot,
  • Vincent Laugel,
  • Juliette Ropars,
  • Cécilia Altuzarra,
  • Caroline Espil-Taris,
  • Ulrike Walther-Louvier,
  • Pascal Sabouraud,
  • Mondher Chouchane,
  • Catherine Vanhulle,
  • Valérie Trommsdorff,
  • Anne Pervillé,
  • Hervé Testard,
  • Emmanuelle Lagrue,
  • Catherine Sarret,
  • Anne-Laude Avice,
  • Pierre Beze-Beyrie,
  • Vanessa Pauly,
  • Susana Quijano-Roy,
  • Brigitte Chabrol,
  • Isabelle Desguerre

DOI
https://doi.org/10.1186/s13023-020-01414-8
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 10

Abstract

Read online

Abstract Background Spinal muscular atrophy (SMA) is an autosomal recessive neuromuscular disorder characterized by degeneration of the anterior horn cells of the spinal cord. Nusinersen has been covered by public healthcare in France since May 2017. The aim of this article is to report results after 1 year of treatment with intrathecal nusinersen in children with SMA types 1 and 2 in France. Comparisons between treatment onset (T0) and after 1 year of treatment (Y1) were made in terms of motor function and need for nutritional and ventilatory support. Motor development milestone achievements were evaluated using the modified Hammersmith Infant Neurologic Examination–Part 2 (HINE-2) for patients under 2 years of age and Motor Function Measure (MFM) scores for patients over 2 years of age. Results Data on 204 SMA patients (type 1 or 2) were retrospectively collected from the 23 French centers for neuromuscular diseases. One hundred and twenty three patients had been treated for at least 1 year and were included, 34 of whom were classified as type 1 (10 as type 1a/b and 24 as type 1c) and 89 as type 2. Survival motor Neuron 2 (SMN2) copy numbers were available for all but 6 patients. Patients under 2 years of age (n = 30), had significantly higher HINE-2 scores at year 1 than at treatment onset but used more nutritional and ventilatory support. The 68 patients over 2 years of age evaluated with the Motor Function Measure test had significantly higher overall scores after 1 year, indicating that their motor function had improved. The scores were higher in the axial and proximal motor function (D2) and distal motor function (D3) parts of the MFM scale, but there was no significant difference for standing and transfer scores (D1). No child in either of the two groups achieved walking. Conclusion Nusinersen offers life-changing benefits for children with SMA, particularly those with more severe forms of the disorder. Caregiver assessments are positive. Nevertheless, patients remain severely disabled and still require intensive support care. This new treatment raises new ethical challenges.

Keywords